NCT07082803 - TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

September 30, 2030

Study Completion Date

November 30, 2030

Conditions

LymphomaLymphoma, Non Hodgkin

Interventions

DRUG

TLN-121

Specified dose on specified days.

DRUG

TLN-254

Specified dose on specified days.

DRUG

TLN-121

Specified dose on specified days.

Trial Locations (8)

2031

NOT_YET_RECRUITING

Prince of Wales Hospital, Randwick

2113

RECRUITING

Macquarie University Hospital, Macquarie Park

3144

RECRUITING

Cabrini Health, Malvern

4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

6009

RECRUITING

Linear Clinical Research, Perth

37203

RECRUITING

SCRI Oncology Partners, Nashville

49546

RECRUITING

The START Center for Cancer Care - Midwest, Grand Rapids

Unknown

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

All Listed Sponsors

lead

Treeline Biosciences, Inc.

INDUSTRY